Genentech/Roche
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| oncology | ×1.15 | 5 |
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| discovery | ×1.50 | 3 |
Strategy profile
Based on 15 disclosed transactions, Genentech/Roche concentrates its licensing activity in Oncology, Metabolic, and Other. Genentech/Roche pays a 1.50x premium over market median, with the strongest premiums in Oncology (1.15x). Their most common deal structure is Collaboration, with an average disclosed value of $1.4B. Most recent activity: 2026.
Premium by therapeutic area
How Genentech/Roche pays relative to peer medians in each TA
Pipeline coverage & gaps
Genentech/Roche has disclosed activity in 1 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| CollaborationPrimary | 8 | $37M | $989M |
| License | 7 | $167M | $1.9B |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | HM17321 | Hanmi Pharmaceuticals | obesity/metabolic | unknown | $190M | $2.3B |
| 2026 | Undisclosed bispecific antibody oncology asset | Earendil Labs | Oncology | discovery | $55M | $1.5B |
| 2026 | — | DualityBio | solid_tumor | preclinical | $45M | $1.0B |
| 2026 | DUPAC novel-payload ADC programs | DualityBio | solid tumors | unknown | $45M | $1.0B |
| 2026 | HM17321 | Hanmi Pharmaceutical | obesity | phase_1 | $190M | $2.3B |
| 2026 | HM17321 | Hanmi Pharm | obesity and related metabolic conditions | preclinical | $190M | $2.3B |
| 2026 | HM17321 | Hanmi Pharm | Obesity and type 2 diabetes | phase_1 | $190M | $2.3B |
| 2026 | HM17321 | Hanmi Pharm | obesity and related metabolic conditions | unknown | $190M | $2.3B |
| 2026 | — | Astex Pharmaceuticals | breast cancer | preclinical | $25M | $515M |
| 2026 | RNAi program | SanegeneBio | other | preclinical | $200M | $1.7B |
| 2025 | — | Caris Life Sciences | precision oncology | discovery | $25M | $1.1B |
| 2025 | Blood-brain barrier (BBB) molecular shuttles platform | Manifold Bio | cns | discovery | $55M | $2.1B |
| 2025 | — | Starpharma | solid_tumor | preclinical | $6M | $570M |
| 2025 | — | OMass Therapeutics | inflammatory bowel disease | discovery | $20M | $420M |
| 2025 | — | Manifold Bio | solid_tumor | discovery | — | $55M |
How this is computed
For each Genentech/Roche deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 6 disclosed deal premiums vs. peer medians. Raw premium 1.496, clamped to [0.7, 1.5].